55 Grosvenor Street
32 articles with Atlas Venture
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
Rectify emerged with a goal to develop disease-modifying precision therapies that will restore ABC transporter function in order to address the underlying cause of serious genetic disease.
Atlas Venture Announces $300 Million Second Opportunity Fund
Atlas Venture today announced the closing of its second Opportunity Fund, raising $300 million in an oversubscribed fundraise.
Atlas Venture Welcomes Samantha Truex as Venture Partner
Atlas Venture, a leading early stage venture capital firm, announced that Samantha Truex is joining the firm as a venture partner.
Atlas Venture Welcomes Rajesh Devraj, PhD, as Venture Partner
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced that Rajesh Devraj, PhD, is joining the firm as a venture partner.
Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise.
With the close of the fund, Atlas Venture said it will continue to advance its mission of “doing well by doing good” and building biotech companies that will deliver high-impact therapies to patients.
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing led by RA Capital Management, with participation from new Investor Abbvie Ventures.
Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing
Atlas Venture announced the launch of Korro Bio, Inc., a new company created to lead the rapidly advancing field of RNA editing.
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
Science2Startup Symposium Will Take Place in Cambridge on April 23, 2019, at the Broad Institute of MIT and Harvard
In a reflection on the annual healthcare conference, VC Bruce Booth criticizes the high cost of attending JPM, as well as the focus on market share instead of patients.
Atlas Venture Announces $250 Million Opportunity Fund
New fund will invest growth capital in Atlas-backed biotech companies
Generation Bio Appoints Jeff Jonas M.D. to its Board of Directors
Generation Bio today announced the appointment of Jeff Jonas, M.D., chief executive officer of Sage Therapeutics, to its Board of Directors.
Atlas Venture Announces Andrea Armstrong Joins as Chief Talent Officer
Andrea will lead the talent acquisition efforts for Atlas and work closely with companies incubating at Atlas and across the emerging portfolio on recruiting and organizational development.
Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner
Nessan will be involved with the formation and leadership of groundbreaking new biotechnology companies as part of the Atlas platform.
Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology